Danish Biotech Stock News

If you are wondering whether TORM's current share price still offers value, you are not alone. This article focuses squarely on what the numbers say about the stock. TORM's stock has seen mixed short term moves, declining 1.6% over the last week but up 9.0% over the last month, while the longer term picture shows a 69.2% return year to date and 96.4% over the last year. Recent attention on TORM has been driven by ongoing interest in the energy and shipping sectors, with investors looking...

If you have been wondering whether A.P. Møller - Mærsk is priced fairly or if the market is missing something, the current setup makes the valuation question especially relevant. The stock last closed at DKK 14,695, with returns of 4.0% over the past week, a decline of 6.6% over the past month, flat performance year to date, and gains of 17.8% over 1 year, 54.1% over 3 years and 66.1% over 5 years. This gives you a mixed picture of recent momentum and longer term performance. Recent news...

Profitability pressure and dividend decision in focus Coloplast (CPSE:COLO B) has drawn fresh attention after reporting second quarter and half year results that combined higher sales with a quarterly net loss, while still confirming an interim dividend payout. See our latest analysis for Coloplast. The latest quarterly loss and lower six month net income appear to have weighed on sentiment, with the share price at DKK399.3 and a year to date share price return down 25.56%. The 5 year total...

Earlier this week, Novo Nordisk presented new sub-analyses from its OASIS 4 and STEP UP phase 3 trials at ECO 2026, showing that both oral and high-dose injectable Wegovy produced substantial weight loss and functional improvements in adults with obesity, with safety consistent with the GLP-1 class. The data also indicated that early responders can achieve very large weight reductions, most of the lost weight comes from fat rather than muscle, and oral Wegovy outperformed rival orforglipron...

Dampskibsselskabet Norden (CPSE:DNORD) has drawn attention after reporting Q1 2026 earnings, with sales of US$813.5 million and a sharp drop in net income to US$11.2 million versus US$32.5 million a year earlier. See our latest analysis for Dampskibsselskabet Norden. The Q1 2026 earnings release and the recent ex dividend date have come alongside firm share price momentum, with a 1 month share price return of 12.83% and a 1 year total shareholder return of 60.52%. This suggests recent...

TORM (CPSE:TRMD A) has been drawing investor attention after recent share price moves, with the stock up over the past month and past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for TORM. The recent pullback, with a 1-day share price return down 3.29% and a 7-day share price return down 1.58%, comes after strong momentum, including a 30-day share price return of 12.00% and a year-to-date share price return of 69.17%. The 1-year total...

It's been a good week for NKT A/S ( CPH:NKT ) shareholders, because the company has just released its latest quarterly...

Aktieselskabet Schouw (CPSE:SCHO) released first quarter 2026 results and reaffirmed full year guidance, giving investors fresh data on sales, profitability and management’s expectations for turnover, revenue and EBIT. See our latest analysis for Aktieselskabet Schouw. At a share price of DKK664.0, the stock has seen a 1-day share price return of 1.84%, while the 90-day share price return is down 5.95% and the 1-year total shareholder return is 15.29%. This suggests that recent momentum has...

Novo Nordisk (CPSE:NOVO B) has cancelled a planned rare disease manufacturing facility in Odense valued at about $1.33b and will instead convert the site into a warehouse. The decision marks a shift in how the company is allocating capital and production capacity across its portfolio of treatments, including obesity and rare diseases. At the European Congress on Obesity, new late stage data from the OASIS 4, STEP UP, and SELECT trials highlighted the efficacy of oral and high dose Wegovy for...

Event context and recent share performance Ørsted (CPSE:ORSTED) has drawn fresh investor attention following its recent share performance, with the stock up around 27% year to date and about 19% over the past 12 months. See our latest analysis for Ørsted. Recent share price moves have been mixed, with a 10.8% 90 day share price return and a 27.0% year to date share price return, in contrast with a 54.1% decline in three year total shareholder return. This suggests momentum has picked up only...

Bavarian Nordic (CPSE:BAVA) has opened 2026 with Q1 revenue of DKK 1,057.8 million and Basic EPS of DKK 0.20, while the trailing twelve months show revenue of DKK 5.96 billion and Basic EPS of DKK 14.86. This sets a clear snapshot of the current run rate. Over recent quarters, revenue has moved from DKK 2,093.9 million in Q4 2024 to DKK 1,346.6 million in Q1 2025 and DKK 1,057.8 million in Q1 2026. Basic EPS shifted from DKK 10.15 to DKK 2.70 and then DKK 0.20. The latest release therefore...

A lackluster earnings announcement from Trifork Group AG ( CPH:TRIFOR ) last week didn't sink the stock price. Our...

H+H International A/S ( CPH:HH ) shareholders are probably feeling a little disappointed, since its shares fell 2.5% to...

Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...

The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...

RTX (CPSE:RTX) has just posted Q2 2026 results with revenue of 164.3 million DKK and Basic EPS of 1.3 DKK, against a backdrop of trailing 12 month revenue of 581.7 million DKK and EPS of 1.45 DKK that marks a clear contrast with the loss reported in Q1 2026. Over recent quarters the company has seen revenue move from 165.5 million DKK in Q2 2025 to 146.7 million DKK in Q4 2025, then to 115.9 million DKK in Q1 2026 and now 164.3 million DKK. EPS shifted from 0.99 DKK to 0.57 DKK, then a loss...

Q1 results and reaffirmed margin outlook put Pandora in focus Pandora (CPSE:PNDORA) is in the spotlight after reporting Q1 2026 earnings showing sales of DKK 7,109 million and net income of DKK 942 million, while reiterating full year EBIT margin guidance of 21% to 22%. See our latest analysis for Pandora. The reaffirmed EBIT margin guidance comes as Pandora's share price trades at DKK 516.2, with a 1 day share price return of 1.02% but a year to date share price decline of 25.79%. The 1 year...

A.P. Møller & Mærsk (CPSE:MAERSK B) is rerouting vessels away from the Strait of Hormuz in response to escalating Middle East tensions. The company is restructuring trade routes to keep cargo moving while limiting exposure to a key geopolitical flashpoint. This shift is part of a broader move toward more flexible, resilient global supply chains. For a stock like CPSE:MAERSK B, where investors track both freight trends and geopolitical risk, this operational shift is highly relevant. The...

NKT (CPSE:NKT) has opened 2026 with Q1 revenue of €864 million and basic EPS of €1.08, alongside trailing 12 month revenue of €3.6 billion and EPS of €5.00 that frame the latest quarterly print in a wider earnings context. Over recent periods, the company has reported quarterly revenue between €837 million and €945 million, with basic EPS ranging from €0.95 to €1.77, while trailing 12 month EPS has been in a range of €4.19 to €5.00 as revenue moved from €3.3 billion to €3.6 billion. This...

Københavns Lufthavne (CPSE:KBHL) has opened 2026 with Q1 revenue of DKK 1.2 billion and basic EPS of DKK 19.00, set against trailing 12 month EPS of DKK 162.52. Over the past year, the company has seen revenue move from DKK 5.07 billion to DKK 5.65 billion and EPS climb from DKK 129.46 to DKK 162.52, alongside earnings growth of 26.2%. This leaves you looking at a business where higher net profit margins and solid profitability are central to the current earnings story. See our full analysis...

FLSmidth (CPSE:FLS) opened 2026 with Q1 revenue of DKK 3.3b and basic EPS of DKK 18.1, set against a trailing twelve month revenue base of DKK 14.2b and EPS of DKK 24.16 that reflects a 23.3% rise in earnings over the past year. Over recent quarters the company has seen revenue move from DKK 3.7b in Q1 2025 to DKK 3.3b in Q1 2026, while quarterly basic EPS has shifted from DKK 5.44 to DKK 18.1, with that earnings trajectory feeding into higher net profit margins. Overall, these results point...

TORM, ticker CPSE:TRMD A, reported a strong Q1 2026 earnings surge. Geopolitical tensions and the closure of the Strait of Hormuz pushed freight rates to record highs. The company upgraded full year guidance and moved ahead with a fleet renewal plan, adding new vessels. TORM focuses on product tankers that transport refined oil products, so freight disruptions and route changes directly affect its earnings power. With key shipping lanes constrained and rerouted, demand for available,...

As European markets navigate a period of modest gains amidst easing geopolitical tensions and strong corporate earnings, the pan-European STOXX Europe 600 Index reflects a cautiously optimistic sentiment. With potential interest rate hikes on the horizon from the European Central Bank and rising producer price inflation, investors are increasingly attentive to identifying stocks that exhibit resilience and growth potential in this dynamic environment. Exploring undiscovered gems within...